NewsRoom Articles - Page 7 of 241

MondayMay 11, 2026 9:00 am

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), are working within a broader industry shift toward advanced delivery platforms designed to…

MondayMay 11, 2026 9:00 am

The Next Generation of the GLP-1 Revolution Is Already Underway

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel…

MondayMay 11, 2026 9:00 am

The Future of Intoxication Detection May Be in Your Voice

BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (Profile) is…

FridayMay 08, 2026 10:00 am

DOJ Announces Task Force to Combat Tech-Driven Fraud in Health Care

Last week, the U.S. Department of Justice announced a plan to tackle tech-driven fraud in the health care system on the West Coast. The initiative will focus on California, Arizona and Nevada. Their investigations will target fraudulent schemes, especially those executed by digital health firms. The effort will be led by the National Fraud Enforcement Division in collaboration with the offices of the attorneys general in California, Arizona and Nevada. Together, they will form a unit dubbed West Coast Health Care Strike Force. This particular initiative builds on the nationwide enforcement model through which technology firms, individuals and health care providers have been prosecuted and convicted on charges related to defrauding…

ThursdayMay 07, 2026 10:30 am

Pipeline Maturity is Redefining Valuations in Biotech

The biotechnology industry is going through a transformation that is redefining how a company’s value is interpreted. While revenue has traditionally been highly associated with a company’s valuation, clinical-stage progression and a company’s probability of success are being increasingly factored into its valuation. Companies on the front lines of this shift, such as Oncotelic Therapeutics, are leveraging their expertise in the space, and showing how scientific advancement can influence financial positioning. The biotechnology sector is undergoing a meaningful shift in how companies are evaluated, challenging long-standing assumptions about value creation. Traditionally, valuation has been closely tied to revenue generation and…

ThursdayMay 07, 2026 10:00 am

Hantavirus Fatalities on Cruise Ship Draw Attention to This Little-Known Infection

The media is awash with news that a cruise ship, called MV Hondius, has suffered an outbreak of hantavirus. Three fatalities have occurred, with one victim confirmed to have died from this infection. Many people are wondering what this infection is and what they can do to stay safe or what they can do in case they are infected. We provide an explainer of the basics you need to know about this virus. For starters, hantavirus is transmitted by rodents like mice and rats. Infections resulting from this virus are rare in humans, and when they happen, they fall into one of…

ThursdayMay 07, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Files Patent Applications for Voice-Based Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The company has filed patent applications covering 15 novel discoveries in AI-driven voice intoxication detection. The platform analyzes speech patterns to estimate drug and alcohol impairment without physical samples. Initial commercial rollout is targeting mining and aviation via Edge AI kiosk systems, with Broader applications including call centers, law enforcement, and mental health screening. Technology is designed for high-volume, regulated environments where testing is costly and time consuming. The overall global drug and alcohol testing market is projected to reach $4.2 billion by 2033. MindBio Therapeutics…

TuesdayMay 05, 2026 10:00 am

Immunologists Discover How Cancer Reprograms Immune Cells to Support Cancer Growth

Immunotherapy has emerged as a key weapon in the fight against cancer. However, nearly 80% of patients either don’t respond to these treatments or they become unresponsive after initially responding to the immunotherapy. The scientific community has been grappling with how to improve response rates, and a new study uncovering how cancer cells reprogram our immune cells to support cancer growth could provide a key. The study, whose findings were published in Science Immunology, was conducted by a team at the University of Texas at Dallas. The team found that cancer doesn’t just hide from immune cells. Rather, it actively reprograms the immune cells within the tumor microenvironment so that they become suppressed and cannot mount an attack against…

TuesdayMay 05, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent challenges in cardiac care is patient delay in seeking care. HeartBeam is working to address this gap by transforming how ECG data are collected and used through its HeartBeam System. Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends, HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising…

FridayMay 01, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential. The prevalence of cardiovascular risk factors illustrates the scale of the issue. Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource demands. Cardio Diagnostics Holdings (NASDAQ: CDIO) is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized…